Biocept Inc  

(Public, NASDAQ:BIOC)   Watch this stock  
Find more results for BIOC
1.98
+0.03 (1.54%)
Aug 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.90 - 2.00
52 week 1.09 - 4.91
Open 2.00
Vol / Avg. 144,801.00/529,738.00
Mkt cap 37.03M
P/E     -
Div/yield     -
EPS -2.33
Shares 18.70M
Beta     -
Inst. own 11%
Nov 11, 2015
Q3 2015 Biocept Inc Earnings Release (Estimated) Add to calendar
Sep 9, 2015
Biocept Inc at Rodman & Renshaw Global Investment Conference - 2:10PM EDT - Add to calendar
Aug 10, 2015
Q2 2015 Biocept Inc Earnings Call - Webcast
Aug 10, 2015
Q2 2015 Biocept Inc Earnings Release
Jun 8, 2015
Biocept Inc Roadshow - New York
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -5256.10% -11891.81%
Operating margin -5068.23% -10398.68%
EBITD margin - -10210.40%
Return on average assets -82.54% -400.76%
Return on average equity -131.41% -
Employees 42 -
CDP Score - -

Address

Suite 150, 5810 Nancy Ridge Drive
SAN DIEGO, CA 92121-2840
United States - Map
+1-858-3208200 (Phone)
+1-858-3208225 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Biocept, Inc. is a cancer diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor DNA (ctDNA), tests utilizing a standard blood sample. Its marketed tests are OncoCEE-BR for breast cancer CTC enumeration and analysis, OncoCEE-GA for gastric cancer CTC enumeration and analysis and OncoCEE-LU for non-small cell lung cancer, or NSCLC, CTC enumeration and analysis. Its marketed test and the tests under development for the enumeration and analysis of CTCs utilize its Cell Enrichment and Extraction, or CEE, technology, and the tests under development for the detection and analysis of ctDNA utilize the Company's CEE-Selector technology, each performed on a standard blood sample. The CEE technology is an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing real-time biomarker monitoring with a standard blood sample.

Officers and directors

Michael W. Nall President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Mark G. Foletta CPA Interim Chief Financial Officer
Age: 54
Bio & Compensation  - Reuters
Lyle J. Arnold Ph. D. Senior Vice President - Research & Development, Chief Scientific Officer
Age: 68
Bio & Compensation  - Reuters
Veena Singh M.D. Senior Vice President, Senior Medical Director
Age: 40
Bio & Compensation  - Reuters
Raaj Trivedi Vice President - Commercial Operations
Age: 42
Bio & Compensation  - Reuters
David F. Hale Non-Executive Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
M. Faye Wilson CPA, Lead Independent Director
Age: 77
Bio & Compensation  - Reuters
Marsha A. Chandler Ph.D. Independent Director
Age: 69
Bio & Compensation  - Reuters
Bruce E. Gerhardt CPA Independent Director
Age: 63
Bio & Compensation  - Reuters
Bruce A. Huebner Independent Director
Age: 64
Bio & Compensation  - Reuters